



Advances in Colorectal Cancer: An Emerging Personalized Therapeutic Opportunity

Guest Editors:

Dr. Alberto Vannelli

Department of Surgery, Valduce
Hospital, Como, Italy

Dr. Tommaso A. Dragani

Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy

Deadline for manuscript
submissions:

16 December 2024

Message from the Guest Editors

Dear Colleagues,


Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. The cumulative findings of the past years demonstrate the existence of different pathways involved in CRC origin and progression. Due to the heterogeneity of CRC, surgery, chemotherapy, and radiation are ineffective in all cases. The integration of artificial intelligence algorithms into studies linking CRC to diagnosis and therapy will greatly enhance our understanding of the effects of individual-based cancer care. Furthermore, CRC treatment is entering a new era with robotic surgery and novel computer-assisted drug delivery techniques. This Special Issue aims to highlight the advantages and limitations of personalized medicine in CRC therapy. Studies include those that explore current scenarios of personalized medicine and the challenges faced in different countries. Finally, we encourage debates on the future perspectives of personalized medicine in CRC and how it could be integrated into the healthcare system.

Dr. Alberto Vannelli

Dr. Tommaso A. Dragani

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)